Trial Site Detail
Drug: |
CB-839 + Talazoparib |
|||
|---|---|---|---|---|
Trial: |
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Terminated |
|||
MD Anderson Cancer Center1505 Holcombe Blvd. |
Principal Investigator: |
Funda Meric-Bernstam, MD |
|---|---|
Contact: |
Contact: Payal Raulji 713-745-2939 pmraulji@mdanderson.org |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
MD Anderson Cancer Center Website: |
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.